Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cordarone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cordarone | DRUG | - |
Inclusion Criteria: * Be a healthy male or female 18 to 59 years of age, inclusive. Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial and must have a negative serum pregnancy test at screening and upon check-in to the study faci...
Cordarone is a small molecule drug being studied for use in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated for its bioavailability and pharmacokinetic properties in a clinical trial setting.
Cordarone is a small molecule drug. Its specific molecular target has not been disclosed in the available information. The drug is being studied in a Phase 1 clinical trial to assess its relative bioavailability.
Cordarone is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker symbol BAX. The company is conducting clinical research on this drug in healthy volunteers.
Cordarone is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a clinical trial to evaluate its bioavailability.
Cordarone has one completed clinical trial registered under NCT00420953, titled 'Relative Bioavailability of PM101 IV and Cordarone IV'. This Phase 1 study was conducted in Canada with healthy adult participants aged 18 years and older.
Cordarone is being studied in comparison with PM101 in a clinical trial. The trial NCT00420953 evaluates the relative bioavailability of PM101 IV and Cordarone IV, indicating they are distinct formulations being compared in the study.